financetom
Business
financetom
/
Business
/
Indian TikTok clone 'Josh' gets Google, Microsoft backing in $100 million fund raise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Indian TikTok clone 'Josh' gets Google, Microsoft backing in $100 million fund raise
Dec 22, 2020 3:17 AM

The parent of a TikTok copycat from India has raised more than USD 100 million from investors including Alphabet Inc’s Google and Microsoft, months after the Chinese-owned short-video app was banned in the country. The app, Josh, is one of several home-grown short-video platforms that have sprung up since India blocked the wildly popular TikTok in June amidst a border crisis with China, attracting global investor interest in applications filling the gap.

Share Market Live

NSE

Bengaluru-based VerSe Innovation, which owns Josh, is valued at more than USD 1 billion following the investment, it said in a statement.

AlphaWave, a part of global asset manager Falcon Edge Capital, also invested in VerSe, as did existing investors Sofina Group and Lupa Systems, VerSe said, adding that it would use the funds to scale up Josh. VerSe also owns news and content platform Dailyhunt, which offers content in multiple Indian languages.

In September, Indian content-sharing platform ShareChat raised USD 40 million from investors including Twitter Inc and Lightspeed Ventures, in an effort to drive growth for its new short-video app Moj.

Both Josh and Moj have been installed on more than 50 million devices each, according to data from Google’s Play Store.

Google also separately announced the investment in VerSe, adding it had also invested in mobile advertising technology firm InMobi, which runs lock-screen content app Glance and short-video app Roposo.

Google, which had set aside USD 10 billion for digital investments in India, did not provide any financial details for the investments.

First Published:Dec 22, 2020 12:17 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Array Technologies CFO Kurt Wood to Step Down on June 30
Array Technologies CFO Kurt Wood to Step Down on June 30
Jun 10, 2024
04:35 PM EDT, 06/10/2024 (MT Newswires) -- Array Technologies ( ARRY ) said late Monday that Kurt Wood will step down as chief financial officer on June 30 to pursue other business interests. Wood will remain with the solar-tracking equipment company as a consultant through the end of September to assist with the transition. The company said it has begun...
Hawkins Insider Bought Shares Worth $288,907, According to a Recent SEC Filing
Hawkins Insider Bought Shares Worth $288,907, According to a Recent SEC Filing
Jun 10, 2024
04:31 PM EDT, 06/10/2024 (MT Newswires) -- James A Faulconbridge, Director, on June 06, 2024, executed a purchase for 3,300 shares in Hawkins (HWKN) for $288,907. Following the Form 4 filing with the SEC, Faulconbridge has control over a total of 42,017 shares of the company, with 42,017 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/46250/000141588924016220/xslF345X03/form4-06102024_080621.xml ...
Energy Recovery Insider Sold Shares Worth $263,950, According to a Recent SEC Filing
Energy Recovery Insider Sold Shares Worth $263,950, According to a Recent SEC Filing
Jun 10, 2024
04:36 PM EDT, 06/10/2024 (MT Newswires) -- Arve Hanstveit, Director, on June 06, 2024, sold 20,000 shares in Energy Recovery ( ERII ) for $263,950. Following the Form 4 filing with the SEC, Hanstveit has control over a total of 883,182 shares of the company, with 763,182 shares held directly and 120,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1421517/000142151724000129/xslF345X03/wk-form4_1718051656.xml ...
Eli Lilly exec says seeing out of pocket payments for obesity drug in US
Eli Lilly exec says seeing out of pocket payments for obesity drug in US
Jun 10, 2024
June 10 (Reuters) - A top Eli Lilly ( LLY ) executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro. Patrik Jonsson, President of Lilly Diabetes and Obesity, speaking at a Goldman Sachs healthcare conference, said a mid-single digit percentage of patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved